Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference Cambridge, MA, January 12, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented its 2003 accomplishments and 2004 outlook at the 22nd Annual JPMorgan
<B><P>-- Phase 3 ADVANCE study of telaprevir in HCV completes enrollment --<br>
-- Registration program for VX-770 in cystic fibrosis being discussed with global authorities --<br>
-- As of September 30, 2008, Vertex had $920 million of cash, cash equivalents and marketable securities--</P></B>
-- Treatment-failure data and treatment-naive data strengthen<br> telaprevir's potential profile and highlight broad opportunity<br> in treatment of chronic hepatitis C virus (HCV) infection<br><br> -- VX-770, for cystic fibrosis (CF), completes enrollment for<br> 28-day Phase 2a study; 2009 targeted for initiation of<br> registration studies, pending 28-day study results
<i><b>-Primary endpoints of safety, tolerability and effect on CFTR
function as measured by sweat chloride-</b></i>
<br />
<i><b>-Phase 2a proof of mechanism clinical trial to enroll people with
the most common mutation of cystic fibrosis, known as F508del-</b></i>
<br />
<i><b>- Primary endpoints of safety and tolerability to be evaluated in
Phase 2a clinical trial -</b></i><i><b>- Measurements of CFTR function to be assessed as secondary
endpoints -</b></i><i><b>- Trial to enroll approximately 90 patients with the F508del CFTR
mutation -</b></i>
<i><b>-Registration program to evaluate improvements in lung function
(FEV</b></i><sub><i><b>1</b></i></sub><i><b>), restoration of CFTR
activity and safety-</b></i><i><b>-Program designed to support registration in cystic fibrosis
patients with the G551D mutation and to provide first evaluation of
activity in patients with F508del mutations-</b></i><i><b>-Primary endpoint for patients with G551D mutation is improvement
in FEV</b></i><sub><i><b>1 </b></i></sub><i><b>through 24 weeks-</b></i>
Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in
Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer Cambridge, MA, and Germantown, MD, February 15, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Avalon Pharmaceuticals Incorporated today announced that